Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Research & Development (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Research & Development for 13 consecutive years, with $93113.0 as the latest value for Q1 2026.

  • Quarterly Research & Development fell 21.22% to $93113.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $456089.0 through Jan 2026, up 12.37% year-over-year, with the annual reading at $438416.0 for FY2025, 7.6% up from the prior year.
  • Research & Development for Q1 2026 was $93113.0 at PharmaCyte Biotech, down from $141085.0 in the prior quarter.
  • The five-year high for Research & Development was $254065.0 in Q2 2022, with the low at $45393.0 in Q1 2023.
  • Average Research & Development over 5 years is $120931.9, with a median of $104483.0 recorded in 2023.
  • The sharpest move saw Research & Development plummeted 71.28% in 2023, then soared 179.19% in 2024.
  • Over 5 years, Research & Development stood at $177996.0 in 2022, then crashed by 53.91% to $82033.0 in 2023, then increased by 18.82% to $97470.0 in 2024, then surged by 44.75% to $141085.0 in 2025, then plummeted by 34.0% to $93113.0 in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $93113.0, $141085.0, and $95157.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.